|
Taxolog, Inc., was co-founded
in 1997 by Drs. Robert A. Holton and Lewis L. Metts. The mission of the
company is to develop and commercialize unique drugs based on
pharmacologically powerful taxanes for the treatment of cancer and
other diseases.
Taxolog
is headquartered in Fairfield, N.J., with an additional
state-of-the-art facility in Tallahassee, Fla.,
employing more than 40 executive and scientific
professionals — all of whom contribute their
extensive education and experience to one common
goal: conquering diseases that have previously been
deemed incurable.
Taxolog, Inc., has obtained exclusive rights to
the entire taxane intellectual-property portfolio of Dr. Holton, whose
research at Florida State University has yielded the semi-synthetic
process by which Taxol®, the first taxane anti-cancer agent, is
commercially manufactured. The first successful total synthesis of
Taxol, Dr. Holton's research has resulted in more than 70 patents
protecting the methods of preparation, composition and use of taxanes.
These analogs are new compounds, completely distinct from those already
commercially marketed, and may exhibit previously unseen mechanisms of
activity. Taxolog's research and development focus has been to design
drugs based on these compounds that will address the shortcomings of
those that are currently available to the medical community.
Currently, Taxolog has many new compounds in
development that exhibit outstanding preclinical activity against
drug-resistant tumors.
This promising
data has resulted in three clinical candidates,
currently in Phase I and Phase II Clinical Trials.
Programs are also underway to determine the
efficacy of the less toxic analogs against diseases such as
Alzheimer's, polycystic kidney disease, psoriasis, multiple sclerosis
and rheumatoid arthritis.
Taxolog, Inc., is determined to utilize every research effort available
to ensure a better quality of life for the patients stricken with these
diseases and their families.
back to top of page
|
